ERCC1 and non-small cell lung carcinoma: With the increasing evidence supporting ERCC-1 expression as a marker of platinum resistance and worse prognosis in patients with metastatic NSCLC [31-32], several research groups are planning prospective clinical trials using ERCC1 to guide treatment decisions.